81 related articles for article (PubMed ID: 14499798)
1. Peginterferon and ribavirin in a patient with acute hepatitis C.
Rodríguez-Gómez SJ; de la Serna-Higuera C; Pérez-Villoria A; Martínez-Moreno J; Betancourt-González A; Martín-Arribas MI
Am J Gastroenterol; 2003 Sep; 98(9):2102-3. PubMed ID: 14499798
[No Abstract] [Full Text] [Related]
2. Therapy of acute hepatitis C with interferon-alpha2b plus ribavirin in a health care worker.
Ertem GT; Tulek N; Oral B; Kinikli S
Acta Gastroenterol Belg; 2005; 68(1):104-6. PubMed ID: 15832597
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.
Alfaleh FZ; Hadad Q; Khuroo MS; Aljumah A; Algamedi A; Alashgar H; Al-Ahdal MN; Mayet I; Khan MQ; Kessie G
Liver Int; 2004 Dec; 24(6):568-74. PubMed ID: 15566506
[TBL] [Abstract][Full Text] [Related]
4. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.
Hasan F; Asker H; Al-Khaldi J; Siddique I; Al-Ajmi M; Owaid S; Varghese R; Al-Nakib B
Am J Gastroenterol; 2004 Sep; 99(9):1733-7. PubMed ID: 15330911
[TBL] [Abstract][Full Text] [Related]
6. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C.
Baker DE
Rev Gastroenterol Disord; 2003; 3(2):93-109. PubMed ID: 12776006
[TBL] [Abstract][Full Text] [Related]
7. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.
Poynard T; McHutchison J; Manns M; Myers RP; Albrecht J
Hepatology; 2003 Aug; 38(2):481-92. PubMed ID: 12883493
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
9. Antiviral therapy for chronic hepatitis C.
Sievert W
Aust Fam Physician; 2003 Oct; 32(10):826-32. PubMed ID: 14596080
[No Abstract] [Full Text] [Related]
10. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
von Wagner M; Huber M; Berg T; Hinrichsen H; Rasenack J; Heintges T; Bergk A; Bernsmeier C; Häussinger D; Herrmann E; Zeuzem S
Gastroenterology; 2005 Aug; 129(2):522-7. PubMed ID: 16083709
[TBL] [Abstract][Full Text] [Related]
11. Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT.
Jacobson IM; Ahmed F; Russo MW; Lebovics E; Dieterich DT; Esposito SP; Bach N; Klion F; Tobias H; Antignano L; Brown RS; Gabbaizadeh D; Geders J; Levendoglu H
Am J Gastroenterol; 2004 Sep; 99(9):1700-5. PubMed ID: 15330905
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hepatitis C.
Heathcote J; Main J
J Viral Hepat; 2005 May; 12(3):223-35. PubMed ID: 15850462
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection.
Hung CH; Lee CM; Lu SN; Wang JH; Tung HD; Chen CH; Changchien CS
J Gastroenterol Hepatol; 2005 May; 20(5):727-32. PubMed ID: 15853986
[TBL] [Abstract][Full Text] [Related]
14. A randomized trial of a 4- vs 12-week daily interferon dose regimen combined with ribavirin in treatment of patients with chronic hepatitis C.
Sarin SK; Goyal A; Kumar S; Guptan RC; Hashmi AZ; Sakhuja P; Malhotra V
Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):42-8. PubMed ID: 14969836
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan.
Yu ML; Dai CY; Lin ZY; Lee LP; Hou NJ; Hsieh MY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Liver Int; 2006 Feb; 26(1):73-81. PubMed ID: 16420512
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV.
Andriulli A; Mangia A
N Engl J Med; 2007 Oct; 357(16):1660; author reply 1661-2. PubMed ID: 17942881
[No Abstract] [Full Text] [Related]
17. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV.
Liu CH; Chen DS; Kao JH
N Engl J Med; 2007 Oct; 357(16):1661; author reply 1661-2. PubMed ID: 17948345
[No Abstract] [Full Text] [Related]
18. Effect of interferon, ribavirin and ursodeoxycholic acid in patients with hepatitis C infection.
Ljubuncic P; Konikoff FM; Blendis LM; Bomzon A
Hepatogastroenterology; 2005; 52(64):1191-6. PubMed ID: 16001659
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C: FDA public meeting on peginterferon plus ribavirin, Nov. 14.
AIDS Treat News; 2002 Oct; (384):5. PubMed ID: 12434764
[No Abstract] [Full Text] [Related]
20. Hepatitis C infections. From diagnosis to treatment.
Shobokshi OA
Saudi Med J; 2003 Jul; 24 Suppl 2():S65-6. PubMed ID: 12897902
[No Abstract] [Full Text] [Related]
[Next] [New Search]
